ClinicalTrials.gg
CompletedNCT05685264Updated Oct 1, 2024Results posted

A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults

A Phase 1 interventional study of Ponsegromab and Ponsegromab in Healthy, sponsored by Pfizer. Completed at 2 sites in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this clinical trial is to learn about the safety of the study medicine (ponsegromab) and how it undergoes change and elimination in healthy Chinese adults. This study is seeking male and female Chinese participants who are very healthy as confirmed after some medical tests.

All participants in this study will receive Ponsegromab only once:

  • for half of the participants, ponsegromab will be given as a shot in the front of the thigh, abdomen, or outer area of the upper arm at the study clinic.
  • for another half of the participants, ponsegromab will be given as four shots in the front of the thigh, abdomen, or outer area of the upper arm at the study clinic.

We will measure the amount of the study medicine in the blood of the participants after giving the shots. Later we will examine experiences of people receiving the study medicine. This will help us understand how the medicine is changed and eliminated from your body and to decide if the study medicine is safe. Participants will take part in this study for 22 weeks. During this time, they will stay at the study clinic for the first 8 days and will visit the study clinic about 8 times.

02

Conditions studied

  • Healthy

Keywords

  • Ponsegromab
  • Healthy Volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be 18 to 55 years of age, inclusive, at the time of signing the
  2. Male and female Chinese participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, BP and PR measurement, 12-lead , and laboratory tests. Chinese participants are defined as individuals currently residing in mainland China who were born in China and have both parents of Chinese descent.
  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  4. of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
  5. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Document..

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. History of infection, syphilis, , or ; positive testing for HIV, syphilis, HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
  3. History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody or molecules made of components of monoclonal antibodies.
  4. History of recurrent infections or active infection within 28 days of screening.
  5. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  6. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg, contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  7. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  8. Exposure to within 28 days of screening.
  9. Previous administration with an drug within 30 days (or as determined by the local requirement) or marketed or investigational monoclonal antibodies within 3 months or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  10. A positive urine drug test.
  11. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  12. Screening 12-lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline interval >450 msec, or QRS interval >120 msec). If the baseline uncorrected QT interval is >450 msec, this interval should be rate-corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
  13. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • or ALT level ≥1.5 × ;
    • Total level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
  14. COVID-19 positive.
  15. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 240 mL beer, 30 mL of 40% spirit or 90 mL of wine).
  16. Blood donation (excluding plasma donations) of approximately 400 mL or more within 60 days prior to dosing.
  17. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  18. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Ponsegromab low dose

    Drug: Ponsegromab

  • Experimental
    Ponsegromab high dose

    Drug: Ponsegromab

Interventions

  • Participants will receive one subcutaneous injection

  • Participants will receive four subcutaneous injections

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Unbound and Total Ponsegromab

    AUCinf was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127

  2. Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Unbound and Total Ponsegromab

    AUClast was defined as area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration.

    Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127

  3. Maximum Observed Serum Concentration (Cmax) of Unbound and Total Ponsegromab

    Cmax was defined as maximum observed concentration. Cmax was observed directly from data.

    Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127

  4. Time for Cmax (Tmax) of Unbound and Total Ponsegromab

    Tmax was defined as time for Cmax. Tmax was observed directly from data as time of first occurrence.

    Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127

  5. Terminal Half Life (t1/2) of Unbound and Total Ponsegromab

    t1/2 was defined as terminal half life. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.

    Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127

Secondary outcomes

  1. Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect.

    Time frame: From the first dose of study intervention on Day 1 to Day 127

  2. Number of Participants With Treatment-Related TEAEs and SAEs

    AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect. Causality of the TEAEs and SAEs was judged by the investigator.

    Time frame: From the first dose of study intervention on Day 1 to Day 127

  3. Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

    Hematology parameters included hemoglobin, hematocrit, red blood cell, white blood cell and platelet count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean platelet volume, total neutrophils, eosinophils, monocytes, basophils and lymphocytes. Chemistry parameters included blood urea nitrogen, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatinine. Urine parameters included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy. Only those categories in which at least 1 participant had data were reported.

    Time frame: From the first dose of study intervention on Day 1 to Day 127

  4. Number of Participants With Clinically Significant Change in Vital Signs

    Vital sign measurements included supine blood pressure and pulse rate. Any safety assessments (vital sign measurements) including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator or were considered meeting the AE definition and are listed below.

    Time frame: From the first dose of study intervention on Day 1 to Day 127

  5. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)

    ECG abnormalities criteria included: 1) maximum QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>30, increase from baseline \>30, \>60; 2) maximum pulse rate (msec): ≥300, baseline \>200 and maximum increase ≥25%, baseline ≤200 and maximum increase ≥50%; 3) maximum QRS (msec): ≥140, increase ≥50%.

    Time frame: From the first dose of study intervention on Day 1 to Day 127

07

Results

Posted Oct 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Started99
Completed99
Not completed00

Outcome measures

PrimaryArea Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Unbound and Total Ponsegromab

AUCinf was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Reported as:
Geometric mean · nanogram (ng)*day/milliliter (mL)
Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Unbound and Total Ponsegromab
nanogram (ng)*day/milliliter (mL)Cohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Unbound ponsegromab109000 ± 58590200 ± 59
Total ponsegromab350300 ± 211105000 ± 44
PrimaryArea Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Unbound and Total Ponsegromab

AUClast was defined as area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration.

Time frame:
Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Reported as:
Geometric mean · ng*day/mL
Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Unbound and Total Ponsegromab
ng*day/mLCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Unbound ponsegromab95170 ± 55647700 ± 60
Total ponsegromab337800 ± 201036000 ± 42
PrimaryMaximum Observed Serum Concentration (Cmax) of Unbound and Total Ponsegromab

Cmax was defined as maximum observed concentration. Cmax was observed directly from data.

Time frame:
Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Reported as:
Geometric mean · ng/mL
Maximum Observed Serum Concentration (Cmax) of Unbound and Total Ponsegromab
ng/mLCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Unbound ponsegromab4698 ± 4121330 ± 64
Total ponsegromab6978 ± 2824910 ± 60
PrimaryTime for Cmax (Tmax) of Unbound and Total Ponsegromab

Tmax was defined as time for Cmax. Tmax was observed directly from data as time of first occurrence.

Time frame:
Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Reported as:
Median · day
Time for Cmax (Tmax) of Unbound and Total Ponsegromab
dayCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Unbound ponsegromab7.01 (5.00 to 14.0)5.00 (3.00 to 14.0)
Total ponsegromab7.01 (3.00 to 14.0)6.99 (3.00 to 28.0)
PrimaryTerminal Half Life (t1/2) of Unbound and Total Ponsegromab

t1/2 was defined as terminal half life. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.

Time frame:
Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Reported as:
Mean · day
Terminal Half Life (t1/2) of Unbound and Total Ponsegromab
dayCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Unbound ponsegromab8.393 ± 2.846110.37 ± 3.7287
Total ponsegromab23.40 ± 3.813531.09 ± 8.9457
SecondaryNumber of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect.

Time frame:
From the first dose of study intervention on Day 1 to Day 127
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
TEAEs47
SAEs00
SecondaryNumber of Participants With Treatment-Related TEAEs and SAEs

AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect. Causality of the TEAEs and SAEs was judged by the investigator.

Time frame:
From the first dose of study intervention on Day 1 to Day 127
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related TEAEs and SAEs
ParticipantsCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
TEAEs01
SAEs00
SecondaryNumber of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

Hematology parameters included hemoglobin, hematocrit, red blood cell, white blood cell and platelet count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean platelet volume, total neutrophils, eosinophils, monocytes, basophils and lymphocytes. Chemistry parameters included blood urea nitrogen, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatinine. Urine parameters included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy. Only those categories in which at least 1 participant had data were reported.

Time frame:
From the first dose of study intervention on Day 1 to Day 127
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
ParticipantsCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Ery. Mean Corpuscular HGB Concentration (g/dL) >1.1 x upper limit of normal (ULN)01
Mean Platelet Volume (fL) <0.9 x lower limit of normal (LLN)42
Lymphocytes (10^3/mm^3) >1.2 x ULN01
Neutrophils (10^9/L) <0.8 x LLN01
Alanine Aminotransferase (U/L) >3.0 x ULN01
Urate (mg/dL) >1.2 x ULN11
pH (Scalar) <1.0 x LLN65
Ketones ≥115
Urine Hemoglobin ≥111
Urobilinogen ≥103
Leukocyte Esterase ≥123
Urine Leukocytes (/uL) >1.0 x ULN11
Epithelial Cells ≥610
SecondaryNumber of Participants With Clinically Significant Change in Vital Signs

Vital sign measurements included supine blood pressure and pulse rate. Any safety assessments (vital sign measurements) including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator or were considered meeting the AE definition and are listed below.

Time frame:
From the first dose of study intervention on Day 1 to Day 127
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Vital Signs
ParticipantsCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Number of Participants With Clinically Significant Change in Vital Signs00
SecondaryNumber of Participants With Clinically Significant Change in Electrocardiogram (ECG)

ECG abnormalities criteria included: 1) maximum QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>30, increase from baseline \>30, \>60; 2) maximum pulse rate (msec): ≥300, baseline \>200 and maximum increase ≥25%, baseline ≤200 and maximum increase ≥50%; 3) maximum QRS (msec): ≥140, increase ≥50%.

Time frame:
From the first dose of study intervention on Day 1 to Day 127
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)
ParticipantsCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)00

Adverse events

Collected over From the first dose of study intervention on Day 1 to Day 127. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Ponsegromab 100 mg0/9 (0%)0/9 (0%)4/9 (44.4%)
Cohort 2: Ponsegromab 400 mg0/9 (0%)0/9 (0%)7/9 (77.8%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventCohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mg
Upper respiratory tract infectionInfections and infestations0/93/9
COVID-19Infections and infestations0/92/9
Alanine aminotransferase increasedInvestigations0/92/9
Urine leukocyte esterase positiveInvestigations0/92/9
Atrioventricular block first degreeCardiac disorders1/90/9
GingivitisInfections and infestations0/91/9
Animal biteInjury, poisoning and procedural complications1/90/9
Aspartate aminotransferase increasedInvestigations0/91/9
Blood uric acid increasedInvestigations1/90/9
Blood glucose increasedInvestigations0/91/9

Baseline characteristics

All enrolled participants who received at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Cohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mgTotal
Median34.0 (27 to 54)25.0 (21 to 51)30.0 (21 to 54)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mgTotal
Female314
Male6814
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Ponsegromab 100 mgCohort 2: Ponsegromab 400 mgTotal
American Indian or Alaska Native000
Asian9918
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 201107, China
  • HuaShan Hospital
    Shanghai, Shanghai 201107, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jul 2023, 5 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2023
First posted
Jan 17, 2023
StartActual
Jan 18, 2023
Primary completionActual
Jul 7, 2023
CompletionActual
Jul 7, 2023
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05685264
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Jan 18, 2023
Primary completion
Jul 7, 2023
Completion
Jul 7, 2023
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponsegromab

Start the discussion